Answers are grounded in this paper and cite their sources.
Predicting breast cancer outcomes remains challenging because of the heterogeneity of clinical and genomic information and the complex interactions among these variables. This study presents a multi-task breast cancer prediction framework based on the Feature Tokenizer Transformer (FT-Transformer) for jointly modelling heterogeneous patient-level information. Feature-specific tokens represent clinical characteristics and genomic alterations, while multi-head self-attention captures nonlinear interactions among the resulting feature representations. A shared Transformer encoder is coupled with task-specific prediction heads for PAM50 subtype classification, ER and HER2 status prediction, relapse prediction, and survival-risk estimation. The model is optimized using a composite objective comprising cross-entropy, binary cross-entropy, and Cox proportional hazards losses. On the held-out METABRIC test set, the ER and HER2 prediction heads achieve accuracies of 93.56% and 89.62%, respectively, while relapse prediction achieves an AUROC of 0.9124 and an AUPRC of 0.8934. Survival-risk estimation achieves a concordance index (C-index) of 0.7963. These task-specific results demonstrate the capability of the proposed framework to learn heterogeneous clinical–genomic relationships across classification, relapse, and time-to-event prediction tasks. Furthermore, attention-based feature attribution provides interpretability by identifying clinical and genomic variables that contribute to individual model predictions. The proposed framework provides a promising computational approach for integrated breast cancer risk assessment and outcome prediction.
No takes yet. Share an insight, caveat, or question.
Banupriya et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: